An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Trial Profile

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Ramucirumab (Primary)
  • Indications Biliary cancer; Bladder cancer; Cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE-098
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Jul 2017 Planned End Date changed from 1 Jul 2018 to 1 Aug 2018.
    • 21 Jul 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Feb 2018.
    • 22 Jun 2017 Planned End Date changed from 15 Jun 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top